RNA
ATRIUM THERAPEUTICS INC
Latest close $11.64 as of Aug 5, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 3 parsed filing(s)| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| BlackRock CIK0002012383 | Jun 30, 2026 observed Jul 27, 2026 filed · 27d Schedule 13G amendment | Reported accumulation | 1.1M +243.4K | 12.00% 0.00 pts | $13.45 | $11.57 | $11.64 |
| BlackRock CIK0002012383 | Mar 31, 2026 observed Apr 27, 2026 filed · 27d Initial Schedule 13G | Initial Schedule 13G | 892.4K | 12.00% | $13.37 | $12.90 | $11.64 |
| T. Rowe Price Associates CIK0000080255 | Mar 31, 2026 observed Apr 8, 2026 filed · 8d Initial Schedule 13G | Initial Schedule 13G | 1.6M | 12.00% | $13.37 | $13.70 | $11.64 |